What is the current Price Target for the Sarepta Therapeutics, Inc. stock?

The average Sarepta Therapeutics, Inc. target price is $100.28. This is 175.27% higher than the current stock price. The highest price target is 407.82%, the lowest is 9.80%. 25 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 .

How high will the Sarepta Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Sarepta Therapeutics, Inc. stock will rise. The performance of stocks, including the Sarepta Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Sarepta Therapeutics, Inc. stock today?

The performance of Sarepta Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Sarepta Therapeutics, Inc. stock fall?

The decline in Sarepta Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

📣 Notice: Short Maintenance Tonight (May 19th)
Due to increasing user numbers, we’re upgrading our servers this evening. StocksGuide will be unavailable for about 5–10 minutes between 4:00 PM and 5:00 PM (EDT / New York time). Afterwards, you’ll continue to benefit from fast and stable site performance. Thank you for your understanding! Your StocksGuide Team

Sarepta Therapeutics, Inc. Forecast, price target & analysts

$36.63

0.55% today

Nasdaq, May 19, 04:18 pm CET

ISIN

US8036071004

Symbol

SRPT

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P MidCap 400

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Sarepta Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Sarepta Therapeutics, Inc. Classifications & Recommendation:

Buy

81%

Hold

19%

Sarepta Therapeutics, Inc. Price Target

Target Price	$100.28
Price	$36.43
Potential	175.27% register free of charge
Number of Estimates	25

	25 Analysts have issued a price target Sarepta Therapeutics, Inc. 2026 . The average Sarepta Therapeutics, Inc. target price is $100.28. This is 175.27% register free of charge higher than the current stock price. The highest price target is $185.00 407.82% register free of charge , the lowest is $40.00 9.80% register free of charge .
	A rating was issued by 27 analysts: 22 Analysts recommend Sarepta Therapeutics, Inc. to buy, 5 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Sarepta Therapeutics, Inc. stock has an average upside potential 2026 of 175.27% register free of charge . Most analysts recommend the Sarepta Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Revenue Billion $	1.90	2.60
	52.97%	36.68%
EBITDA Margin	14.30%	11.70%
	185.10%	18.18%
Net Margin	12.09%	-6.07%
	126.37%	150.22%

24 Analysts have issued a sales forecast Sarepta Therapeutics, Inc. 2025 . The average Sarepta Therapeutics, Inc. sales estimate is

2024	$1.9b	52.97%
2025	$2.6b 36.68% Unlock
2026	$3.0b 15.06% Unlock
2027	$3.2b 7.83% Unlock
2028	$3.1b 3.63% Unlock
2029	$3.2b 3.61% Unlock

2024	$272m	230.17%
2025	$304m 11.85% Unlock
2026	$1.2b 308.62% Unlock
2027	$1.7b 37.45% Unlock
2028	$1.5b 14.60% Unlock
2029	$1.7b 19.71% Unlock

2024	$230m	140.34%
2025	$-158m 168.68% Unlock
2026	$723m 557.74% Unlock
2027	$886m 22.60% Unlock
2028	$772m 12.87% Unlock
2029	$824m 6.78% Unlock

	Dec '24	2025 Estimates
Earnings Per Share $	2.34	-1.61
	140.34%	168.80%
P/E		negative
EV/Sales		1.69

2024	$2.34	140.34%
2025	$-1.61 168.80% Unlock
2026	$7.36 557.14% Unlock
2027	$9.02 22.55% Unlock
2028	$7.86 12.86% Unlock
2029	$8.39 6.74% Unlock

Current	-14.13	100.71%
2025	-22.67 60.44% Unlock
2026	4.95 121.84% Unlock
2027	4.04 18.38% Unlock
2028	4.64 14.85% Unlock
2029	4.34 6.47% Unlock

Current	1.97	77.79%
2025	1.69 14.06% Unlock
2026	1.47 13.08% Unlock
2027	1.36 7.26% Unlock
2028	1.42 3.76% Unlock
2029	1.37 3.48% Unlock

Current	1.60	81.95%
2025	1.38 14.09% Unlock
2026	1.20 13.08% Unlock
2027	1.11 7.26% Unlock
2028	1.15 3.77% Unlock
2029	1.11 3.48% Unlock

Analyst	Rating	Action	Date
Wells Fargo	Locked ➜ Locked	Locked	May 08 2025
Oppenheimer	Locked ➜ Locked	Locked	May 07 2025
Goldman Sachs	Locked ➜ Locked	Locked	May 07 2025
Morgan Stanley	Locked ➜ Locked	Locked	May 07 2025
Needham	Locked ➜ Locked	Locked	May 07 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	May 07 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	May 07 2025

Analyst Rating	Date
Locked Wells Fargo: Locked ➜ Locked	May 08 2025
Locked Oppenheimer: Locked ➜ Locked	May 07 2025
Locked Goldman Sachs: Locked ➜ Locked	May 07 2025
Locked Morgan Stanley: Locked ➜ Locked	May 07 2025
Locked Needham: Locked ➜ Locked	May 07 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	May 07 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	May 07 2025

Sarepta Therapeutics, Inc. Forecast, price target & analysts

Sarepta Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Sarepta Therapeutics, Inc. Classifications & Recommendation:

Sarepta Therapeutics, Inc. Price Target

Sales and Margin forecast 2025, 2026 to 2029

Revenue & Growth

Revenue Estimates

EBITDA, Margin & Growth

EBITDA Estimates

EBITDA Margin

Net Margin

Net Profit Estimates

Net Margin

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Earnings Per Share

Earnings Per Share

P/E ratio

EV/Sales

EV/Sales

P/S ratio

More exciting key metrics

Current Sarepta Therapeutics, Inc. Upgrades & Downgrades

Discover more stocks with a high price target

Register for Free